MX2025001881A - Terapia que comprende anticuerpos anti cumulo de diferenciacion 19 (cd19) y moduladores del homologo 2 del potenciador de la proteina zeste (ezh2) - Google Patents
Terapia que comprende anticuerpos anti cumulo de diferenciacion 19 (cd19) y moduladores del homologo 2 del potenciador de la proteina zeste (ezh2)Info
- Publication number
- MX2025001881A MX2025001881A MX2025001881A MX2025001881A MX2025001881A MX 2025001881 A MX2025001881 A MX 2025001881A MX 2025001881 A MX2025001881 A MX 2025001881A MX 2025001881 A MX2025001881 A MX 2025001881A MX 2025001881 A MX2025001881 A MX 2025001881A
- Authority
- MX
- Mexico
- Prior art keywords
- ezh2
- modulators
- antibody
- therapy
- need
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción proporciona métodos, composiciones farmacéuticas y kits para tratar el cáncer en pacientes que lo necesitan. Los métodos comprenden administrar a un paciente que lo necesita un modulador de EZH2, tal como el Compuesto I o una sal farmacéuticamente aceptable del mismo, en combinación con uno o más anticuerpos anti-CD19. También se proporcionan medicamentos para su uso en el tratamiento del cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263398634P | 2022-08-17 | 2022-08-17 | |
| US202263417812P | 2022-10-20 | 2022-10-20 | |
| PCT/EP2023/072620 WO2024038115A1 (en) | 2022-08-17 | 2023-08-16 | Therapy comprising anti-cd19 antibody and ezh2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001881A true MX2025001881A (es) | 2025-04-02 |
Family
ID=87800924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001881A MX2025001881A (es) | 2022-08-17 | 2025-02-14 | Terapia que comprende anticuerpos anti cumulo de diferenciacion 19 (cd19) y moduladores del homologo 2 del potenciador de la proteina zeste (ezh2) |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4572756A1 (es) |
| JP (1) | JP2025528837A (es) |
| KR (1) | KR20250052388A (es) |
| CN (1) | CN120152716A (es) |
| AU (1) | AU2023326589A1 (es) |
| CA (1) | CA3264686A1 (es) |
| CL (1) | CL2025000432A1 (es) |
| IL (1) | IL318787A (es) |
| MX (1) | MX2025001881A (es) |
| WO (1) | WO2024038115A1 (es) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| WO2008031056A2 (en) | 2006-09-08 | 2008-03-13 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| EA201190132A1 (ru) | 2009-02-23 | 2013-01-30 | Гленмарк Фармасьютикалс С.А. | Гуманизированные антитела, связывающиеся с cd19, и их применение |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP3909985A1 (en) | 2016-06-27 | 2021-11-17 | MorphoSys AG | Anti-cd19 antibody formulations |
| EP3707136B1 (en) | 2017-11-09 | 2022-05-04 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT3781561T (lt) | 2018-04-18 | 2024-07-10 | Constellation Pharmaceuticals, Inc. | Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas |
| WO2019226491A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR102689665B1 (ko) | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| BR112022001154A2 (pt) | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Terapias de inibição de ezh2 para o tratamento de cânceres |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| KR102386403B1 (ko) | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
| WO2022135582A1 (zh) | 2020-12-25 | 2022-06-30 | 王海斌 | 一种按摩珠及其鞋、垫、毯 |
-
2023
- 2023-08-16 JP JP2025508686A patent/JP2025528837A/ja active Pending
- 2023-08-16 AU AU2023326589A patent/AU2023326589A1/en active Pending
- 2023-08-16 CA CA3264686A patent/CA3264686A1/en active Pending
- 2023-08-16 CN CN202380059878.XA patent/CN120152716A/zh active Pending
- 2023-08-16 WO PCT/EP2023/072620 patent/WO2024038115A1/en not_active Ceased
- 2023-08-16 EP EP23761070.4A patent/EP4572756A1/en active Pending
- 2023-08-16 IL IL318787A patent/IL318787A/en unknown
- 2023-08-16 KR KR1020257007411A patent/KR20250052388A/ko active Pending
-
2025
- 2025-02-13 CL CL2025000432A patent/CL2025000432A1/es unknown
- 2025-02-14 MX MX2025001881A patent/MX2025001881A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250052388A (ko) | 2025-04-18 |
| JP2025528837A (ja) | 2025-09-02 |
| IL318787A (en) | 2025-04-01 |
| EP4572756A1 (en) | 2025-06-25 |
| WO2024038115A1 (en) | 2024-02-22 |
| CN120152716A (zh) | 2025-06-13 |
| CA3264686A1 (en) | 2024-02-22 |
| CL2025000432A1 (es) | 2025-06-13 |
| AU2023326589A1 (en) | 2025-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070702L (no) | Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff | |
| AU2018263862A1 (en) | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| AU2010266004A8 (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| SA523440623B1 (ar) | أجسام مضادة | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| WO2022238963A3 (en) | Genetically engineered immune cells targeting cd70 for use in treating solid tumors | |
| IL164564A0 (en) | Combination therapy for the treatment of cancer | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| AU2021339851A8 (en) | Method of treating amyloidosis | |
| BR112022026094A2 (pt) | Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2024007749A (es) | Formulaciones clinicas de anticuerpos anti-tigit. | |
| MX2023013614A (es) | Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial. | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| MX2025001881A (es) | Terapia que comprende anticuerpos anti cumulo de diferenciacion 19 (cd19) y moduladores del homologo 2 del potenciador de la proteina zeste (ezh2) | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
| WO2019241742A8 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |